Answers are grounded in this paper and cite their sources.
Elevated IOP in clinical practice is usually seen in glaucoma or ocular hypertension. Glaucoma affects 60 million people worldwide and 8.4 million are bilaterally blind from this chronic disease.1 Options for reducing IOP rely on pharmacological agents, laser treatments and surgery which may be penetrating or non-penetrating. The last twenty years has seen significant changes in all of these strategies. This review aims to cover these clinical options and introduce some of the new technologies currently in development for the clinical lowering of IOP.
No takes yet. Share an insight, caveat, or question.
Crawley et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: